News Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 20/04/2026 BST			5-day change	1st Jan Change
86.93 ^USD	-0.89%		-1.81%	+11.72%

04-13	Kymera Therapeutics Wins FDA Fast Track for Oral Asthma Drug	MT
04-13	Kymera Therapeutics, Inc. Announces U.S. FDA Fast Track Designation for KT-621, A First-In-Class, Oral Stat6 Degrader for the Treatment of Moderate to Severe Asthma	CI

All News

04-13	Kymera Therapeutics Wins FDA Fast Track for Oral Asthma Drug	MT
04-13	Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma	AQ
04-13	Kymera Therapeutics, Inc. Announces U.S. FDA Fast Track Designation for KT-621, A First-In-Class, Oral Stat6 Degrader for the Treatment of Moderate to Severe Asthma	CI
04-09	Kymera to Receive $45 Million Milestone Payment as Gilead Exercises Option to License KT-200	MT
04-09	Kymera Therapeutics announces Gilead Sciences' option exercise to license KT-200, oral CDK2 molecular glue degrader development candidate	RE
04-09	Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate	AQ
04-09	Kymera Therapeutics and Gilead Sciences Enter License Agreement for Kt-200 with $45 Million Milestone Payment	CI
03-30	Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology Annual Meeting	AQ
03-28	Kymera Therapeutics Presents KT-621 BroADen Data In Late-Breaking Research Session At The American Academy Of Dermatology Annual Meeting	CI
03-28	Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting	AQ
03-12	Kymera Therapeutics, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-12-2026 09:30 AM
03-11	Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology Annual Meeting	AQ
03-10	Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting	AQ
03-03	UBS Adjusts Price Target on Kymera Therapeutics to $128 From $90, Maintains Buy Rating	MT
02-26	Kymera Therapeutics, Inc., Q4 2025 Earnings Call, Feb 26, 2026
02-26	Kymera Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-26	Kymera Therapeutics : Corporate Presentation, February 2026	PU
02-26	Kymera Therapeutics Appoints Neil Graham, MBBS, MD, MPH, as Chief Development Officer	CI
02-26	Kymera Therapeutics Q4 Loss Widens, Revenue Falls	MT
02-26	Earnings Flash (KYMR) Kymera Therapeutics Posts Q4 Net Loss $0.97 a Share, vs. FactSet Est of $0.78 Loss	MT
02-26	Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q4 Revenue $2.9M	MT
02-26	Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q4 Revenue $2.9M	MT
02-26	Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update	AQ
02-25	Kymera Therapeutics Insider Sold Shares Worth $2,707,813, According to a Recent SEC Filing	MT
02-24	Kymera Therapeutics to Participate in Upcoming March Investor Conferences	AQ